法匹拉韦联合洛匹那韦-利托那韦在COVID-19患者中的群体药动/药效学建模评价
本研究基于2a期随机双盲2×2析因安慰剂对照FLARE试验的次要终点,建立群体药动学和病毒动力学模型,分别纳入59和235名参与者,评估法匹拉韦联合洛匹那韦-利托那韦的抗病毒效果。结果显示法匹拉韦与洛匹那韦-利托那韦联用使法匹拉韦表观清除率增加两倍,但两药对感染细胞死亡速率均无显著影响,提示在所研究剂量下法匹拉韦对SARS-CoV-2无抗病毒活性。
要点
- 法匹拉韦联合洛匹那韦-利托那韦使法匹拉韦表观清除率增加两倍,存在意外药物相互作用。
- 两药对感染细胞死亡速率δ均无改善模型拟合的作用,提示无抗病毒效果。
- 病毒全基因组测序未显示明确的致突变特征。
核心结论
- 法匹拉韦在本研究所用剂量下对SARS-CoV-2无抗病毒活性。
- 法匹拉韦与洛匹那韦-利托那韦联用存在意外的药物相互作用,需进一步研究其机制。
研究设计与样本
- 基于2a期随机、双盲、2×2析因、安慰剂对照FLARE试验的次要终点分析。
- 群体药动学模型纳入59名参与者,病毒动力学模型纳入235名参与者。
- 进行了病毒全基因组测序。
主要发现
- 最终联合模型由斜率-截距指数衰减病毒动力学模型和法匹拉韦一室模型(一级吸收和消除)组成。
- 感染细胞平均死亡速率δ为0.96 day-1。
- 法匹拉韦平均表观清除率(CL/F)为1.73 L/h,平均表观分布容积为22.1 L。
- 法匹拉韦与洛匹那韦-利托那韦联用使CL/F增加两倍。
- 法匹拉韦和洛匹那韦-利托那韦对δ的药物效应未改善最终联合模型的拟合。
临床怎么用
- 临床不应期望法匹拉韦在所研究剂量下对SARS-CoV-2具有抗病毒疗效。
- 联用洛匹那韦-利托那韦时需注意法匹拉韦清除率增加两倍,可能影响暴露量。
局限性
- 本研究为次要终点分析,样本量有限(药动学59人,病毒动力学235人)。
- 药物相互作用机制尚未明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The repurposed use of favipiravir in COVID-19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans. In this study, we report the secondary endpoints from the phase 2a randomized, double-blind, 2 × 2 factorial placebo-controlled FLARE trial, which studied the combination of favipiravir and lopinavir-ritonavir. METHODS: Population pharmacokinetic and viral dynamic models including data from 59 and 235 participants respectively were developed to assess the drug effect of favipiravir in combination with lopinavir-ritonavir. Viral whole-genome sequencing was performed. RESULTS: The final joint model consisted of a slope-intercept exponential decay viral dynamic model and a one-compartment model with first-order absorption and elimination for favipiravir pharmacokinetics. The mean death rate of infected cells (δ) was 0.96 day-1. Favipiravir mean apparent clearance (CL/F) and mean apparent volume of distribution were 1.73 L/h and 22.1 L, respectively. Favipiravir co-administration with lopinavir-ritonavir increased CL/F by twofold, representing an unexpected drug-drug interaction. Favipiravir and lopinavir-ritonavir drug effects on δ did not improve model fit in the final joint model, indicating that neither drug has any antiviral effect against SARS-CoV-2. Viral sequencing did not show a clear mutagenic signature. CONCLUSIONS: Our findings suggest that favipiravir does not have antiviral activity at the dose used in our study, and further work to understand the mechanistic basis of the drug-drug interaction with lopinavir-ritonavir is required.
引用
- Agyeman AA, Buggiotti L, Brown LK, et al. Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir-ritonavir in patients with COVID-19. Br J Clin Pharmacol. 2026. PMID: 41869741. doi:10.1002/bcp.70507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。